Mobile Site ›
Print Friendly View

Test ID: POX    
Fatty Acid Profile, Peroxisomal (C22-C26), Serum

Useful For Suggests clinical disorders or settings where the test may be helpful

Evaluating patients with possible peroxisomal disorders, including peroxisomal biogenesis disorders, X-linked adrenoleukodystrophy, and Refsum disease

 

An aid in the assessment of peroxisomal function

Genetics Test Information Provides information that may help with selection of the correct test or proper submission of the test request

Reports include concentrations of C22:0, C24:0, C26:0 species, phytanic acid and pristanic acid, and calculated C24:0/C22:0, C26:0/C22:0, and phytanic acid/pristanic acid ratios.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Peroxisomes are organelles present in all human cells except mature erythrocytes. They carry out essential metabolic functions including beta-oxidation of very long-chain fatty acids (VLCFA), alpha-oxidation of phytanic acid, and biosynthesis of plasmalogen and bile acids. Peroxisomal disorders include disorders of peroxisomal biogenesis with defective assembly of the entire organelle and single peroxisomal enzyme/transporter defects where the organelle is intact but a specific function is disrupted. Peroxisomal beta-oxidation of VLCFA is impaired in all disorders of peroxisomal biogenesis and in selected single enzyme deficiencies, particularly X-linked adrenoleukodystrophy (X-ALD), resulting in elevated concentrations of VLCFA in plasma or serum.

 

Peroxisomal biogenesis disorders (PBD) include the Zellweger syndrome spectrum disorders that are clinically diverse and range in severity from neonatal lethal (Zellweger syndrome) to more variable clinical courses in neonatal adrenoleukodystrophy and infantile Refsum disease. Affected children typically have hypotonia, poor feeding, distinctive facial features, seizures, and liver dysfunction. Other features can include retinal dystrophy, hearing loss, developmental delays, and bleeding episodes. Rhizomelic chondrodysplasia punctata is another PBD. It is characterized by rhizomelic shortening, chondrodysplasia punctata, cataracts, intellectual disability, and seizures, although it can have a milder phenotype with only cataracts and chondrodysplasia. The typical biochemical profile shows normal VLCFA and elevated phytanic acid.

 

X-ALD is a neurologic disorder affecting the white matter and adrenal cortex. It can present between ages 4 and 8 as a childhood cerebral form with behavioral and cognitive changes, associated with neurologic decline. Other forms include an "Addison disease only" phenotype with adrenocortical insufficiency without initial neurologic abnormality and adrenomyeloneuropathy associated with later-onset progressive paraparesis. X-ALD is an X-linked condition that primarily affects males; however, some females who are carriers can develop later-onset neurologic manifestations. 

 

Refsum disease is a peroxisomal disorder characterized by anosmia, retinitis pigmentosa, neuropathy, deafness, ataxia, ichthyosis, and cardiac abnormalities. The classic biochemical profile of Refsum disease is an elevated plasma or serum phytanic acid level.

 

Biochemical abnormalities in peroxisomal disorders include accumulations of VLCFA, phytanic, and pristanic acid. The differential diagnosis of these disorders is based on recognition of clinical phenotypes combined with a series of biochemical tests to assess peroxisomal function and structure. These include measurements and ratios of VLCFA, pipecolic acid (PIPA / Pipecolic Acid, Serum; PIPU / Pipecolic Acid, Urine), phytanic acid and its metabolite pristanic acid.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

C22:0

< or =96.3 nmol/mL

 

C24:0

< or =91.4 nmol/mL

 

C26:0

< or =1.30 nmol/mL

 

C24:0/C22:0 RATIO

< or =1.39

 

C26:0/C22:0 RATIO

< or =0.023

 

PRISTANIC ACID

0-4 months: < or =0.60 nmol/mL

5-8 months: < or =0.84 nmol/mL

9-12 months: < or =0.77 nmol/mL

13-23 months: < or =1.47 nmol/mL

> or =24 months: < or =2.98 nmol/mL

 

PHYTANIC ACID

0-4 months: < or =5.28 nmol/mL

5-8 months: < or =5.70 nmol/mL

9-12 months: < or =4.40 nmol/mL

13-23 months: < or =8.62 nmol/mL

> or =24 months: < or =9.88 nmol/mL

 

PRISTANIC/PHYTANIC ACID RATIO

0-4 months: < or =0.35

5-8 months: < or =0.28

9-12 months: < or =0.23

13-23 months: < or =0.24

> or =24 months: < or =0.39

Interpretation Provides information to assist in interpretation of the test results

Reports include concentrations of C22:0, C24:0, C26:0 species, phytanic acid and pristanic acid, and calculated C24:0/C22:0, C26:0/C22:0, and phytanic acid:pristanic acid ratios. When no significant abnormalities are detected, a simple descriptive interpretation is provided.

 

A profile of elevated phytanic acid, low-normal pristanic acid, and normal very long-chain fatty acids is suggestive of Refsum disease (phytanic acid oxidase deficiency); however, serum phytanic acid concentration may also be increased in disorders of peroxisomal biogenesis and should be considered in the differential diagnosis of peroxisomal disorders.

 

If results are suggestive of hemizygosity for X-linked adrenoleukodystrophy, we also include the calculated value of a discriminating function used to more accurately segregate hemizygous individuals from normal controls.

 

Positive test results could be due to genetic or nongenetic condition. Additional confirmatory testing would be required.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

In rare instances, patients with X-linked adrenoleukodystrophy (X-ALD) may have only minimally elevated values; 15% to 20% of women heterozygous for X-ALD have normal plasma very long-chain fatty acid levels.

 

False-positive results may occur with nonfasting specimens.

Clinical Reference Provides recommendations for further in-depth reading of a clinical nature

1. Moser AB, Kreiter N, Bezman L, et al: Plasma very long chain fatty acid assay in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol 1999;45:100-110

2. Wanders RJA: Inborn Errors of Peroxisome Biogenesis and Function. In Pediatric Endocrinology and Inborn Errors of Metabolism. Edited by K Sarafoglou, GF Hoffmann, KS Roth, New York, NY, McGraw-Hill Medical Division, 2009, pp 323-337